7 results about "Increase blood pressure" patented technology

This invention discloses an environmental parameter sensing and adaptive adjustment system and method based on a photoconductive film. It integrates six-dimensional environmental sensors—light intensity, ultraviolet radiation, temperature, humidity, air pressure, and air quality—at the edge of the photoconductive film, and utilizes the film's directional light guidance and stray light filtering mechanisms to reduce environmental interference. The system includes an environmental sensing module, an environmental parameter processing module, a health data interface module, a correlation analysis module, an adaptive adjustment module, and an environmental early warning module. The correlation analysis module has preset environmental-health correlation patterns such as low temperature-increased blood pressure, high humidity-decreased blood oxygen, high ultraviolet radiation-skin health, poor air quality-respiratory diseases, and sudden changes in air pressure-headaches and joint pain, set based on clinical research data. The adaptive adjustment module pairs with smart home devices through a unified identity authentication center, sending control commands via Wi-Fi / Bluetooth / infrared to automatically adjust air conditioners, humidifiers, dehumidifiers, air purifiers, and lighting according to environmental parameters. The environmental early warning module supports single-indicator early warning, correlation early warning, trend early warning, and seasonal disease early warning, with customizable thresholds. The multi-environmental data fusion module uses weighted averaging and the 3σ principle for anomaly removal, integrating data from multiple devices such as mobile phones, watches, vehicles, and smart home devices. The sensors are automatically calibrated daily using meteorological bureau data, with the calibration process simultaneously linked to health data. This invention solves the problems of scattered environmental sensing devices, disconnect from health data, and inability to proactively adjust, serving as the infrastructure for intelligent health management.

The invention provides a health management method based on hypertensive patient data supervision. The treatment compliance and management efficiency of hypertensive patients are improved through intelligent means. Multi-dimensional health data such as blood pressure, heart rate and movement of a patient are collected in real time through the wearable device, and the data are uploaded to the cloud platform to be stored and integrated. By means of big data analysis and an artificial intelligence algorithm, variability analysis, trend prediction and anomaly detection are conducted on the blood pressure data, and the health state of the patient is accurately evaluated. And according to an analysis result, the system generates a personalized health management scheme which comprises drug adjustment suggestions, diet and exercise guidance and psychological intervention measures. The patient terminal APP pushes health suggestions and propaganda and education contents in real time, and medical staff remotely monitor patient data through the medical terminal APP and provide real-time intervention. The innovation point of the system lies in multi-dimensional data integration, intelligent analysis and prediction, personalized intervention and a doctor-patient interaction platform, and the treatment compliance and the blood pressure standard-reaching rate of the hypertensive patient are improved.

Application of a central polypeptide angiotensin-(5-7) in the preparation of a drug. The present invention demonstrates that Ang-(5-7) in the RVLM of WKY rats can enhance sympathetic output and increase blood pressure, and part of Ang-(5-7) acts on the AT1 receptor to participate in the central regulation of blood pressure. Further exploring the mechanism of action of Ang-(5-7) in the sympathetic center, it is found that Ang-(5-7) in the RVLM of WKY rats can enhance sympathetic output and increase blood pressure through the oxidative stress pathway, while targeting and interfering with the expression of DPP3 in the RVLM endogenously reduces Ang-(5-7) under the pathological state of hypertension, improves oxidative stress, and reduces the blood pressure of SHR rats. The research of the present invention shows that Ang-(5-7) enhances sympathetic output and increases blood pressure through the oxidative stress pathway and participates in the central regulation of the cardiovascular activities of patients.

The present application provides a method for assessing the risk of blood pressure during pregnancy, an electronic device, and a readable storage medium, and relates to the field of terminal technology. The method is applied to electronic devices, including: obtaining the prediction results of the blood circulation status, mental health status, and blood pressure fluctuation status of the next pregnancy cycle in the current pregnancy cycle; determining the risk assessment score of the blood pressure in the next pregnancy cycle based on the prediction results of the blood circulation status, mental health status, and blood pressure fluctuation status; when the risk assessment score is in the first interval, determining the blood pressure in the next pregnancy cycle as a risk-free level; when the risk assessment score is in the second interval, determining the blood pressure in the next pregnancy cycle as a risky level. Based on the above technical solution, the electronic device can predict and assess the blood pressure risk level of the next pregnancy cycle in the current pregnancy cycle, and can remind the user to seek medical treatment in time when there is a risk, which helps the user pay attention to their own health and prevent high blood pressure during pregnancy.

Provided herein are methods of stabilizing blood pressure in severe sepsis / septic shock and other types of distributive shock using TRPV1 agonists. Also provided are pharmaceutical formulations for increasing blood pressure in septic shock the formulation including at least one TRPV1 agonist in a dosage form for parenteral administration, wherein the TRPV1 agonist is selected from capsaicin, daphnane TRPV1 agonists, vanillotoxin, N-oleoyl dopamine, N-arachidonyl dopamine, BrP-LPA, and derivatives and analogues thereof. Also provided are TRPV1 agonists co-lyophilized with adrenergic agonists and / or angiotensins in a dosage form for reconstitution and parenteral administration.

The invention provides a brain-computer interface-based hypertensive drug dynamic monitoring system and a brain-computer interface-based hypertensive drug dynamic monitoring method, designs a novel hypertensive drug dynamic monitoring mechanism, and analyzes the drug effect by mixing the electroencephalogram signal, the blood pressure signal and the drug taking time to form a multi-modal signal. A series of optimization settings continue to be matched from the aspect of details, so that through multi-modal fusion, dynamic modeling, personalized optimization and clinical closed loop, the system comprehensively surpasses the prior art in the aspects of monitoring dimension, decision depth and function integration, and through collaborative analysis of nerve-blood pressure-autonomic nerve, the accuracy of the system is improved. The normal form transformation of hypertension treatment from symptomatic administration to nerve-body fluid-blood vessel coordinated regulation is promoted, and the accuracy, individuation and safety of hypertension drug monitoring are remarkably improved.

The present invention pertains to the field of nutraceuticals, specifically to a synergistic nutraceutical composition designed to improve cardio-metabolic health. The composition, comprising berberine, anthocyanin(s), and astaxanthin, is intended to regulate aberrant metabolic biomarkers, including hyperglycemia, hypertriglyceridemia, elevated low-density lipoprotein (LDL) cholesterol, increased blood pressure, enhanced platelet aggregation, elevated serum transaminase activity and hypoadiponectinemia. This invention is particularly applicable to the therapeutic management of cardiometabolic pathologies, including Type 2 Diabetes Mellitus (T2DM), arterial hypertension, dyslipidemia, atherosclerosis, obesity, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), cerebrovascular accidents (stroke), and coronary artery disease, through the modulation of systemic metabolic homeostasis and by providing potential adjunctive efficacy alongside established pharmacotherapeutic regimens.